prednisone + rituximab

Prednisone + rituximab is a combination therapy consisting of two distinct drugs with complementary mechanisms of action. Prednisone is a synthetic glucocorticoid corticosteroid that suppresses inflammation and modulates immune responses by binding to the glucocorticoid receptor, thereby inhibiting multiple inflammatory cytokines and immune pathways. Rituximab is a chimeric monoclonal antibody targeting the CD20 antigen on B lymphocytes, leading to B-cell depletion through complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and induction of apoptosis. This combination has been used in various autoimmune diseases (such as pemphigus vulgaris and immune thrombocytopenic purpura) where rapid immunosuppression (from prednisone) is paired with longer-term disease control via B-cell depletion (from rituximab). The regimen has demonstrated superior efficacy compared to corticosteroids alone in certain conditions like pemphigus vulgaris[1][2][4].

Brand names

Rituxan + Prednisone

Other names

Steroid + rituximabGlucocorticoid + rituximab